Home › Acute Monocytic Leukemia
Acute Monocytic Leukemia clinical trials recruiting in the U.S.
8 studies for Acute Monocytic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RecruitingPhase 2
Ages 1 to 60 · All sexes · Updated Oct 20, 2026 · NCT03970096Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06504459Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT03737955Halt Aging in Survivors of Blood Cancers
Recruiting
Ages 50 and older · All sexes · Updated Jul 1, 2026 · NCT07292272211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03670966A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT06950034Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Jan 15, 2026 · NCT06429449From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.